NCT02098551 is a clinical trial of SPT and APT in Atopic Dermatitis, sponsored by Stefan Woehrl.

Who is sponsoring NCT02098551?

NCT02098551 is sponsored by Stefan Woehrl.

What drugs are being tested in NCT02098551?

Interventions in NCT02098551: SPT and APT.

What condition does NCT02098551 study?

NCT02098551 studies Atopic Dermatitis.

Is NCT02098551 still recruiting?

NCT02098551 is currently completed. Last updated 6 December 2015.

Last reviewed 2015-12-06 · How we verify

NCT02098551

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Skin Testing With Recombinant Bet v 1 and Hypoallergenic Recombinant Bet v 1 Fragments to Dissect the Contribution of IgE to Chronic Allergic Skin Inflammation

Completed Last updated 6 December 2015

What this trial tests

trial testing SPT and APT in Atopic Dermatitis in 30 participants. Completed in 1 April 2013.

Timeline

1 February 2011

Primary endpoint
1 November 2011

1 April 2013

Quick facts

Lead sponsor	Stefan Woehrl
Status	Completed
Study type	OBSERVATIONAL
Enrollment	30
Start date	1 February 2011
Primary completion	1 November 2011
Estimated completion	1 April 2013
Sites	1 location across Austria

Drugs / interventions tested

SPT and APT

Conditions studied

Atopic Dermatitis — all drugs for Atopic Dermatitis →

Sponsor

Stefan Woehrl

Who can join

Adults 18 to 75, any sex, with Atopic Dermatitis. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Number of Participants with Positive Atopy Patch Testing Reactions of Each Grade on the European Task Force on Atopic Dermatitis Scale
Time frame: 6 months
Birch pollen extract (BPE), as well as rBet v 1 (160mg), rBet v 1 fragment 1 (160mg), rBet v 1 fragment 2 (160mg), and an equimolar rBet v 1 fragment mix (80mg of each rBet v 1 fragment), were applied for 48h in patch test chambers onto nonlesional skin on the backs of the subjects. After 48h, patches were removed, and reactions were analyzed and photodocumented. Grading of positive APT reactions

Sponsor's own description

Aim of this study is to use the major allergen 1 of birch-tree pollen (Bet v 1, Betula verrucosa, synonymous Betula pendula), to investigate the contribution of immunoglobulin E (IgE)- versus non-IgE-mediated mechanisms to chronic skin inflammation in atopic dermatitis patients.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Epicutaneous allergen application preferentially boosts specific T cell responses in sensitized patients.
Campana R, Moritz K, Neubauer A, Huber H, et al · · 2017 · cited 17× · PMID 28912492 · DOI 10.1038/s41598-017-10278-1
Heat-labile Escherichia coli toxin enhances the induction of allergen-specific IgG antibodies in epicutaneous patch vaccination.
Cabauatan CR, Campana R, Niespodziana K, Reinisch C, et al · · 2017 · cited 10× · PMID 27568860 · DOI 10.1111/all.13036

Verify or expand the search:

Other recruiting trials for Atopic Dermatitis

Currently open trials in the same condition.

NCT07262983 — Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopi · Phase 1 · recruiting
NCT07445919 — A Clinical Study to Evaluate SM17 for Atopic Dermatitis · Phase 2 · recruiting
NCT07488065 — A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants · Phase 1 · recruiting
NCT07467564 — The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatit · recruiting
NCT07358156 — A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and E · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02098551 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Stefan Woehrl
Last refreshed: 6 December 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02098551.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing